Provectus Pharmaceuticals Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of their drug – PV-10 – for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. The same drug is currently undergoing Phase 2 study for metastatic melanoma.

The primary objective of the open-label study is to determine the safety and tolerability of a single intralesional injection of PV-10 in patients with liver cancer. Additional objectives are to assess the distribution and retention of PV-10 in the injected lesion, tumor response and viability, and plasma pharmacokinetics of the drug following intralesional injection.

The CEO of Provectus, Dr. Craig Dees, PhD, spoke about the Phase 1 trial, “We hope to demonstrate that PV-10, which has shown excellent selectivity for melanoma, will be a viable therapeutic for liver cancer and cancers metastatic to the liver.”

The

Provectus Pharmaceuticals, Inc.

(Public, OTC:PVCT)

StocksHaven Investments profiles one of the most exciting up-and-coming anti-cancer companies in the industry, Provectus Pharmaceuticals (OTC:PVCT). They have one of the deepest pipelines of any small cap biotech, focusing on treatments for: Melanoma, Psoriasis, Atopic Dermatitis, Breast Cancer, and Liver Metastasis. With three drugs nearly ready to enter Phase III, including one nearly entering Phase II for Breast Cancer, one of the largest target markets worldwide and seeking “compassionate use” in Australia and USA, look for Provectus to make a splash within the next couple of months.

They are developing and testing one of the most exciting anti- cancer compounds. It has been demonstrating significant effectiveness against Melanoma in Phase 2 clinical trials and it offers promising treatment for breast, liver and other solid tumor based metastatic cancers. The compound developed by Provectus, known as PV-10, is a

Provectus Pharmaceuticals Inc. is quickly gaining a reputation as an up-and-coming development-stage oncology and dermatology biopharmaceutical company. Helping to enhance this reputation and its position in the marketplace, Provectus announced the addition of Mount Sinai School of Medicine as the second and final site for its expanded Phase 2 clinical trial of the company’s lead dermatology agent PH-10 for psoriasis. Jason Elmer, M.D., who served as the lead investigator for the Phase 2 clinical trial of PH-10 for atopic dermatitis of which patent enrollment was completed in June, will also serve as the principal investigator of this trial.

Commenting on the value of Dr. Elmer’s work on this project, Provectus CEO Craig Dees, Ph.D. stated, “Dr. Emer’s work with PH-10 for atopic dermatitis, his involvement in the ongoing research of the product as a dermatological therapy, and Mount Sinai School of Medicine’s outstanding reputation in dermatological research make this

Stock-PR OTC Stock Report August 18, 2009

Insight Management Corporation (OTCBB: ISIM) President and CEO, Jennifer Rapacki, August 18, 2009 commented on positive trends in the domestic natural gas services market. “While existing natural gas wells continue to demand maintenance, new drilling activity should create added demands for service,” Ms. Rapacki noted. “We are now seeing an increase in leasing activity and are very encouraged about how that will translate into higher revenues for service companies like ours in the remainder of this year.”

Sector 10, Inc. (OTCBB:SECI) (Frankfurt:4SR) announced that it has submitted proposals to multiple cities regarding the deployment of the Pilot PLX-3D system. The proposals were sent in response to inquiries received from the announcement of the Pilot PLX-3D deployment program in the July 21, 2009 press release. The PLX-3D deployment and the related installation of SRU’s are designed to help communities better prepare for emergencies, disasters and

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

Tuesday August 18, 2009

PennyOmega.com Stock Report!

**************************************************************

Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, has added Mount Sinai School of Medicine as its second and final site for its expanded Phase 2 clinical trial of the Company’s lead dermatology agent PH-10 for psoriasis. Jason Emer, M.D. will serve as principal investigator of the trial; he is also the lead investigator for the Phase 2 clinical trial of PH-10 for atopic dermatitis, for which patient enrollment was completed in June.

Consistent with its ongoing efforts to enhance services offered to its customers and contract services clients, SouthWest Water Company (NASDAQ:SWWC), a leading provider of

Yesterday, Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, held its 2009 Annual Meeting of Shareholders in Knoxville, Tennessee. During the meeting, shareholders voted to re-elect the company’s five members of the Board of Directors, which is composed of three inside directors, and two outside directors. Each Director serves a one-year term.

Dr. Dees, CEO of Provectus commented, “We appreciate the confidence of our shareholders as Provectus continues to achieve its milestones for the development of PV-10 and PH-10. Our recently reported ASCO data support our mission to continue our quest to find a viable, safe and effective treatment for metastatic melanoma, and further our research towards that end. Having completed patient accrual in May for our phase 2 melanoma trial, we look forward to communicating additional results to the scientific community and investors in coming months.”

Dr. Dees continued, “While our primary focus has been directed towards

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) announced that they have commenced recruitment for their Phase 2 clinical trial of the company’s lead oncology agent PV-10 at a fifth major center, now covering the northeastern United States. The new center joins the other company’s centers located in Sydney, Brisbane and Adelaide, Australia, and Houston, Texas.

Sanjiv Agarwala, M.D. has been appointed as the principal investigator at the new center, located at St. Luke’s Hospital & Health Network, in Bethlehem, PA. Over the next several months, the company intends to continue expansion of the study to include sites in other major population centers in Australia as well as several sites in the United States.

Phase 2 clinical testing of PV-10 is designed to assess the agent as a treatment for Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study will

Provectus Chairman and CEO, Craig Dees, Ph.D, first hosts a luncheon on Oct. 29, starting at Noon at the Hyatt Regency (151 E. Wacker Drive) in Chicago, Ill. Dees will then present twice in New York City. The first will be at the Wall Street Analyst Forum, from Nov. 17-19 at the University Club, 1 W 54th St. He will then present at the 12th Annual New York Society of Security Analysts (NYSSA) Biotechnology/ Specialty Pharmaceutical Industry Conference, Dec. 2-3 (location TBA).

“As Provectus continues to make significant strides in developing our oncological and dermatological therapies, we continue to strive to increase investor awareness and visibility of the company,” Dees said.

Dees has spent more than 20 years in senior management positions at Provectus Pharmaceuticals, Inc.; Photogen Technologies, Inc.; the Oak Ridge National Laboratory; LipoGen, Inc.; and TechAmerica, Inc. Dees was a founder, senior scientist and founding director of Photogen before Provectus

Provectus Pharmaceuticals Inc. (OTCBB: PVCT) specializes in effective, affordable and minimally invasive oncology and dermatology therapies to treat diseases such as melanoma and psoriasis. The company today announced it is recruiting for its phase 2 clinical trials of PV-10 for the treatment of stage III and IV metastatic melanoma, the most deadly form of skin cancer.

The company is focusing on recruiting 80 subjects at a fourth center in Adelaide, Australia to test the efficacy of PV-10. Throughout the next several months, Provectus expects to expand its study to incorporate subjects in other areas of Australia, as well as several sites in the United States.

“Opening the center at Adelaide is the continuation of our expansion of our phase 2 program in melanoma to multiple sites including the U.S.,” Craig Dees, Ph.D., CEO of Provectus stated in the press release. “It is another important step in our effort to get

Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. The announcement of a peer-reviewed paper entitled “Chemoablation of metastatic melanoma using intralesional Rose Bengal,” which can be found on the Provectus website, will soon be published in the December issue of “Melanoma Research.”

Our Director of Marketing had the great fortune to see Provectus Pharmaceuticals up close and in person during a recent conference and sat aghast as they unveiled cancer after cancer being treated and then cured by their PV-10 drug. If you have a moment to take a look at the clinical photos of the melanoma research, we highly recommend it. The paper presents the clinical data for the first 11 subjects in Phase 1 trial.

According to the paper, twenty-six target lesions were injected with PV-10, and an additional 28